1. Masters EA, Hao SP, Kenney HM, Morita Y, Galloway CA, de Mesy Bentley KL, et al. Distinct vasculotropic versus osteotropic features of S. agalactiae versus S. aureus implant-associated bone infection in mice. J Orthop Res. 2021 Feb; 39(2): 389-401. DOI: 10.1002/jor.24962 [ DOI] [ PubMed] 2. Tavares GC, de Queiroz GA, Assis GBN, Leibowitz MP, Teixeira JP, Figueiredo HCP, et al. Disease outbreaks in farmed Amazon catfish (Leiarius marmoratus x Pseudoplatystoma corruscans) caused by Streptococcus agalactiae, S. iniae, and S. dysgalactiae. Aquaculture. 2018; 495: 384-92. DOI: 10.1016/j.aquaculture.2018.06.027 [ Article] [ DOI] 3. Groot J, Blegvad C, Nybo Andersen AM, Zachariae C, Jarløv JO, Skov L. Presence of streptococci and frequent tonsillitis among adolescents with psoriasis. Br J Dermatol. 2021 Apr; 184(4): 758-59. DOI: 10.1111/bjd.19672 [ DOI] [ PubMed] 4. Cavaillon JM. Exotoxins and endotoxins: Inducers of inflammatory cytokines. Toxicon. 2018 Jul; 149: 45-53. DOI: 10.1016/j.toxicon.2017.10.016 [ DOI] [ PubMed] 5. González-Abad MJ, Sanz MA. Invasive Streptococcus pyogenes infections (2011–2018): EMM-type and clinical presentation. An Pediatr (Barc). 2020; 92(6): 351-58. DOI: 10.1016/j.anpede.2019.10.006 [ Article] [ DOI] 6. Armstrong AW, Read C. Pathophysiology, Clinical Presentation, and Treatment of Psoriasis: A Review. JAMA. 2020 May; 323(19): 1945-60. DOI: 10.1001/jama.2020.4006 [ DOI] [ PubMed] 7. De Jesús-Gil C, Sans-de San Nicolás L, Ruiz-Romeu E, Ferran M, Soria-Martinez L, Chiriac A, et al. Specific IgA and CLA+ T-Cell IL-17 Response to Streptococcus pyogenes in Psoriasis. J Invest Dermatol. 2020 Jul; 140(7): 1364-70.e1. DOI: 10.1016/j.jid.2019.12.022 [ DOI] [ PubMed] 8. Okada K, Matsushima Y, Mizutani K, Yamanaka K. The Role of Gut Microbiome in Psoriasis: Oral Administration of Staphylococcus aureus and Streptococcus danieliae Exacerbates Skin Inflammation of Imiquimod-Induced Psoriasis-Like Dermatitis. Int J Mol Sci. 2020 May; 21(9): 3303. DOI: 10.3390/ijms21093303 [ DOI] [ PubMed] 9. Blauvelt A. IL-6 differs from TNF-α: unpredicted clinical effects caused by IL-6 blockade in psoriasis. Journal of Investigative Dermatology. 2017; 137(3): 541-42. DOI: 10.1016/j.jid.2016.11.022 [ Article] [ DOI] 10. Singh S, Dogra S, Shafiq N, Bhansali A, Malhotra S. Prevalence of Metabolic Syndrome in Psoriasis and Levels of Interleukin-6 and Tumor Necrosis Factor-α in Psoriasis Patients with Metabolic Syndrome: Indian Tertiary Care Hospital Study. Int J Appl Basic Med Res. 2017 Jul-Sep; 7(3): 169-75. DOI: 10.4103/ijabmr.IJABMR_330_16 [ DOI] [ PubMed] 11. Al-Shibly IK, Al-Sultany HA. Streptococcalsuper antigens and LL-37 antimicrobial peptide as an immune mediatoramong psoriasis patients in Iraq. Annals of Tropical Medicine and Public Health. 2020; 23: 231-811. DOI: 10.36295/ASRO.2020.231811 [ Article] [ DOI] 12. Nazari A, Khalili M B, Astani A, Vakili M, Sadeh M, Mojibiyan M, et al. Determination of Genotypes of Streptococcus Agalactiae Isolated from both Urine and Vagina of Pregnant Women Referred to Gynecology Clinics of Yazd, Iran -2015. International Journal of Medical Laboratory. 2017; 4(3): 180-88. [ View at Publisher] 13. Yamamoto M, Ferretti JJ. High level expression of Streptococcus pyogenes erythrogenic toxin A (SPE A) in Escherichia coli and its rapid purification by HPLC. FEMS Microbiol Lett. 1995 Oct; 132(3): 209-13. DOI: 10.1111/j.1574-6968.1995.tb07835.x [ DOI] [ PubMed] 14. Molinari G, Chhatwal GS. Streptococcal invasion. Curr Opin Microbiol. 1999 Feb; 2(1): 56-61. DOI: 10.1016/s1369-5274(99)80010-1 [ DOI] [ PubMed] 15. Hauser AR, Stevens DL, Kaplan EL, Schlievert PM. Molecular analysis of pyrogenic exotoxins from Streptococcus pyogenes isolates associated with toxic shock-like syndrome. J Clin Microbiol. 1991 Aug; 29(8): 1562-67. DOI: 10.1128/jcm.29.8.1562-1567.1991 [ DOI] [ PubMed] 16. Hung CH, Tsao N, Zeng YF, Lu SL, Chuan CN, Lin YS, et al. Synergistic effects of streptolysin S and streptococcal pyrogenic exotoxin B on the mouse model of group A streptococcal infection. Med Microbiol Immunol. 2012 Aug; 201(3): 357-69. DOI: 10.1007/s00430-012-0241-6 [ DOI] [ PubMed] 17. Munz OH, Sela S, Baker BS, Griffiths CE, Powles AV, Fry L. Evidence for the presence of bacteria in the blood of psoriasis patients. Arch Dermatol Res. 2010 Sep; 302(7): 495-98. DOI: 10.1007/s00403-010-1065-0 [ DOI] [ PubMed] 18. Krueger GG. Psoriasis therapy--observational or rational? N Engl J Med. 1993 Jun; 328(25): 1845-46. DOI: 10.1056/NEJM199306243282511 [ DOI] [ PubMed] 19. Raychaudhury SP. Recent advances in psoriasis: bench to bedside. Indian J Dermatol. 2010 Apr-Jun; 55(2): 150. DOI: 10.4103/0019-5154.62749 [ DOI] [ PubMed] 20. Liang YS, Wen HQ, Xiao R. [Serum levels of antibodies for IgG, IgA, and IgM against the fungi antigen in psoriasis vulgaris]. Hunan Yi Ke Da Xue Xue Bao. 2003 Dec; 28(6): 638-40. [Article in Chinese] [ PubMed] 21. Passàli D, Lauriello M, Passàli GC, Passàli FM, Bellussi L. Group A streptococcus and its antibiotic resistance. Acta Otorhinolaryngol Ital. 2007 Feb; 27(1): 27-32. [ View at Publisher] 22. McCormick JK, Pragman AA, Stolpa JC, Leung DY, Schlievert PM. Functional characterization of streptococcal pyrogenic exotoxin J, a novel superantigen. Infect Immun. 2001 Mar; 69(3): 1381-88. DOI: 10.1128/IAI.69.3.1381-1388.2001 [ DOI] [ PubMed] 23. Norgren M, Norrby A, Holm SE. Genetic diversity in T1M1 group A streptococci in relation to clinical outcome of infection. J Infect Dis. 1992 Nov; 166(5): 1014-20. DOI: 10.1093/infdis/166.5.1014 [ DOI] [ PubMed] |
